Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy</title><author><name sortKey="Kim, Sang Won" sort="Kim, Sang Won" uniqKey="Kim S" first="Sang-Won" last="Kim">Sang-Won Kim</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Radiation Oncology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8674 9741</institution-id><institution-id institution-id-type="GRID">grid.411143.2</institution-id><institution>Department of Radiation Oncology,</institution><institution>Konyang University College of Medicine,</institution></institution-wrap>158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Chun, Mison" sort="Chun, Mison" uniqKey="Chun M" first="Mison" last="Chun">Mison Chun</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Radiation Oncology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Ryu, Hee Sug" sort="Ryu, Hee Sug" uniqKey="Ryu H" first="Hee-Sug" last="Ryu">Hee-Sug Ryu</name><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Obstetrics and Gynecology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Chang, Suk Joon" sort="Chang, Suk Joon" uniqKey="Chang S" first="Suk-Joon" last="Chang">Suk-Joon Chang</name><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Obstetrics and Gynecology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Kong, Tae Wook" sort="Kong, Tae Wook" uniqKey="Kong T" first="Tae Wook" last="Kong">Tae Wook Kong</name><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Obstetrics and Gynecology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Oh, Young Taek" sort="Oh, Young Taek" uniqKey="Oh Y" first="Young-Taek" last="Oh">Young-Taek Oh</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Radiation Oncology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Kang, Seung Hee" sort="Kang, Seung Hee" uniqKey="Kang S" first="Seung Hee" last="Kang">Seung Hee Kang</name><affiliation><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5112</institution-id><institution-id institution-id-type="GRID">grid.411612.1</institution-id><institution>Department of Radiation Oncology, Ilsan Paik Hospital,</institution><institution>Inje University School of Medicine,</institution></institution-wrap>170 Juhwa-ro, Ilsanseo-gu, Goyang, Gyeonggi-do 10380 Republic of Korea</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28454573</idno><idno type="pmc">5410059</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410059</idno><idno type="RBID">PMC:5410059</idno><idno type="doi">10.1186/s12885-017-3299-0</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">000C43</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000C43</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy</title><author><name sortKey="Kim, Sang Won" sort="Kim, Sang Won" uniqKey="Kim S" first="Sang-Won" last="Kim">Sang-Won Kim</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Radiation Oncology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8674 9741</institution-id><institution-id institution-id-type="GRID">grid.411143.2</institution-id><institution>Department of Radiation Oncology,</institution><institution>Konyang University College of Medicine,</institution></institution-wrap>158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Chun, Mison" sort="Chun, Mison" uniqKey="Chun M" first="Mison" last="Chun">Mison Chun</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Radiation Oncology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Ryu, Hee Sug" sort="Ryu, Hee Sug" uniqKey="Ryu H" first="Hee-Sug" last="Ryu">Hee-Sug Ryu</name><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Obstetrics and Gynecology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Chang, Suk Joon" sort="Chang, Suk Joon" uniqKey="Chang S" first="Suk-Joon" last="Chang">Suk-Joon Chang</name><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Obstetrics and Gynecology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Kong, Tae Wook" sort="Kong, Tae Wook" uniqKey="Kong T" first="Tae Wook" last="Kong">Tae Wook Kong</name><affiliation><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Obstetrics and Gynecology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Oh, Young Taek" sort="Oh, Young Taek" uniqKey="Oh Y" first="Young-Taek" last="Oh">Young-Taek Oh</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Radiation Oncology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</nlm:aff></affiliation></author><author><name sortKey="Kang, Seung Hee" sort="Kang, Seung Hee" uniqKey="Kang S" first="Seung Hee" last="Kang">Seung Hee Kang</name><affiliation><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5112</institution-id><institution-id institution-id-type="GRID">grid.411612.1</institution-id><institution>Department of Radiation Oncology, Ilsan Paik Hospital,</institution><institution>Inje University School of Medicine,</institution></institution-wrap>170 Juhwa-ro, Ilsanseo-gu, Goyang, Gyeonggi-do 10380 Republic of Korea</nlm:aff></affiliation></author></analytic><series><title level="j">BMC Cancer</title><idno type="eISSN">1471-2407</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>The aim of the present study was to investigate the long-term survival outcomes and toxicities associated with our experienced early administration of adjuvant concurrent chemoradiotherapy (CCRT).</p></sec><sec><title>Methods</title><p>Ninety-eight patients with pelvic lymph node metastasis, positive resection margin, and/or parametrial invasion who received adjuvant CCRT between 1995 and 2011 were analyzed retrospectively. The first cycle of platinum-based adjuvant chemotherapy was initiated within 2–3 weeks after surgery (median, 12 days) and continued every 4 weeks for a total of 4 cycles. Adjuvant radiotherapy was performed during the second and third cycles of chemotherapy.</p></sec><sec><title>Results</title><p>After a median follow-up period of 119 months for survivors, 13 patients (13.3%) experienced recurrence and 11 patients died of cancer during the follow-up period. The 5-year recurrence-free survival and cancer specific survival rates were 87.6% and 90.6%, respectively. Ninety-four patients (95.9%) received ≥3 cycles of chemotherapy. Total radiation dose of ≥45 Gy was delivered in 91 patients (92.9%). Grade 3–4 hematologic and gastrointestinal toxicities developed in 37 (37.8%) and 14 (14.3%) patients during CCRT, respectively.</p></sec><sec><title>Conclusion</title><p>The present study confirmed the long-term safety and encouraging survival outcomes of early administration of adjuvant CCRT, suggesting the benefits of early time to initiation of adjuvant treatments.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Landoni, F" uniqKey="Landoni F">F Landoni</name></author><author><name sortKey="Maneo, A" uniqKey="Maneo A">A Maneo</name></author><author><name sortKey="Colombo, A" uniqKey="Colombo A">A Colombo</name></author><author><name sortKey="Placa, F" uniqKey="Placa F">F Placa</name></author><author><name sortKey="Milani, R" uniqKey="Milani R">R Milani</name></author><author><name sortKey="Perego, P" uniqKey="Perego P">P Perego</name></author><author><name sortKey="Favini, G" uniqKey="Favini G">G Favini</name></author><author><name sortKey="Ferri, L" uniqKey="Ferri L">L Ferri</name></author><author><name sortKey="Mangioni, C" uniqKey="Mangioni C">C Mangioni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Inoue, T" uniqKey="Inoue T">T Inoue</name></author><author><name sortKey="Okumura, M" uniqKey="Okumura M">M Okumura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alvarez, Rd" uniqKey="Alvarez R">RD Alvarez</name></author><author><name sortKey="Soong, Sj" uniqKey="Soong S">SJ Soong</name></author><author><name sortKey="Kinney, Wk" uniqKey="Kinney W">WK Kinney</name></author><author><name sortKey="Reid, Gc" uniqKey="Reid G">GC Reid</name></author><author><name sortKey="Schray, Mf" uniqKey="Schray M">MF Schray</name></author><author><name sortKey="Podratz, Kc" uniqKey="Podratz K">KC Podratz</name></author><author><name sortKey="Morley, Gw" uniqKey="Morley G">GW Morley</name></author><author><name sortKey="Shingleton, Hm" uniqKey="Shingleton H">HM Shingleton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fuller, Af" uniqKey="Fuller A">AF Fuller</name></author><author><name sortKey="Elliott, N" uniqKey="Elliott N">N Elliott</name></author><author><name sortKey="Kosloff, C" uniqKey="Kosloff C">C Kosloff</name></author><author><name sortKey="Hoskins, Wj" uniqKey="Hoskins W">WJ Hoskins</name></author><author><name sortKey="Lewis, Jl" uniqKey="Lewis J">JL Lewis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sevin, Bu" uniqKey="Sevin B">BU Sevin</name></author><author><name sortKey="Lu, Y" uniqKey="Lu Y">Y Lu</name></author><author><name sortKey="Bloch, Da" uniqKey="Bloch D">DA Bloch</name></author><author><name sortKey="Nadji, M" uniqKey="Nadji M">M Nadji</name></author><author><name sortKey="Koechli, Or" uniqKey="Koechli O">OR Koechli</name></author><author><name sortKey="Averette, He" uniqKey="Averette H">HE Averette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zreik, Tg" uniqKey="Zreik T">TG Zreik</name></author><author><name sortKey="Chambers, Jt" uniqKey="Chambers J">JT Chambers</name></author><author><name sortKey="Chambers, Sk" uniqKey="Chambers S">SK Chambers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Estape, Re" uniqKey="Estape R">RE Estape</name></author><author><name sortKey="Angioli, R" uniqKey="Angioli R">R Angioli</name></author><author><name sortKey="Madrigal, M" uniqKey="Madrigal M">M Madrigal</name></author><author><name sortKey="Janicek, M" uniqKey="Janicek M">M Janicek</name></author><author><name sortKey="Gomez, C" uniqKey="Gomez C">C Gomez</name></author><author><name sortKey="Penalver, M" uniqKey="Penalver M">M Penalver</name></author><author><name sortKey="Averette, H" uniqKey="Averette H">H Averette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Yj" uniqKey="Kim Y">YJ Kim</name></author><author><name sortKey="Lee, Kj" uniqKey="Lee K">KJ Lee</name></author><author><name sortKey="Park, Kr" uniqKey="Park K">KR Park</name></author><author><name sortKey="Kim, J" uniqKey="Kim J">J Kim</name></author><author><name sortKey="Jung, W" uniqKey="Jung W">W Jung</name></author><author><name sortKey="Lee, R" uniqKey="Lee R">R Lee</name></author><author><name sortKey="Kim, Sc" uniqKey="Kim S">SC Kim</name></author><author><name sortKey="Moon, Hs" uniqKey="Moon H">HS Moon</name></author><author><name sortKey="Ju, W" uniqKey="Ju W">W Ju</name></author><author><name sortKey="Kim, Yh" uniqKey="Kim Y">YH Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sedlis, A" uniqKey="Sedlis A">A Sedlis</name></author><author><name sortKey="Bundy, Bn" uniqKey="Bundy B">BN Bundy</name></author><author><name sortKey="Rotman, Mz" uniqKey="Rotman M">MZ Rotman</name></author><author><name sortKey="Lentz, Ss" uniqKey="Lentz S">SS Lentz</name></author><author><name sortKey="Muderspach, Li" uniqKey="Muderspach L">LI Muderspach</name></author><author><name sortKey="Zaino, Rj" uniqKey="Zaino R">RJ Zaino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rotman, M" uniqKey="Rotman M">M Rotman</name></author><author><name sortKey="Sedlis, A" uniqKey="Sedlis A">A Sedlis</name></author><author><name sortKey="Piedmonte, Mr" uniqKey="Piedmonte M">MR Piedmonte</name></author><author><name sortKey="Bundy, B" uniqKey="Bundy B">B Bundy</name></author><author><name sortKey="Lentz, Ss" uniqKey="Lentz S">SS Lentz</name></author><author><name sortKey="Muderspach, Li" uniqKey="Muderspach L">LI Muderspach</name></author><author><name sortKey="Zaino, Rj" uniqKey="Zaino R">RJ Zaino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morrow, Cp" uniqKey="Morrow C">CP Morrow</name></author><author><name sortKey="Shingleton, Hm" uniqKey="Shingleton H">HM Shingleton</name></author><author><name sortKey="Austin, Jm" uniqKey="Austin J">JM Austin</name></author><author><name sortKey="Averette, He" uniqKey="Averette H">HE Averette</name></author><author><name sortKey="Girtanner, Re" uniqKey="Girtanner R">RE Girtanner</name></author><author><name sortKey="Webb, Mj" uniqKey="Webb M">MJ Webb</name></author><author><name sortKey="Masterson, Jg" uniqKey="Masterson J">JG Masterson</name></author><author><name sortKey="Morley, Gw" uniqKey="Morley G">GW Morley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kinney, Wk" uniqKey="Kinney W">WK Kinney</name></author><author><name sortKey="Alvarez, Rd" uniqKey="Alvarez R">RD Alvarez</name></author><author><name sortKey="Reid, Gc" uniqKey="Reid G">GC Reid</name></author><author><name sortKey="Schray, Mf" uniqKey="Schray M">MF Schray</name></author><author><name sortKey="Soong, Sj" uniqKey="Soong S">SJ Soong</name></author><author><name sortKey="Morley, Gw" uniqKey="Morley G">GW Morley</name></author><author><name sortKey="Podratz, Kc" uniqKey="Podratz K">KC Podratz</name></author><author><name sortKey="Shingleton, Hm" uniqKey="Shingleton H">HM Shingleton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peters, Wa" uniqKey="Peters W">WA Peters</name></author><author><name sortKey="Liu, Py" uniqKey="Liu P">PY Liu</name></author><author><name sortKey="Barrett, Rj" uniqKey="Barrett R">RJ Barrett</name></author><author><name sortKey="Stock, Rj" uniqKey="Stock R">RJ Stock</name></author><author><name sortKey="Monk, Bj" uniqKey="Monk B">BJ Monk</name></author><author><name sortKey="Berek, Js" uniqKey="Berek J">JS Berek</name></author><author><name sortKey="Souhami, L" uniqKey="Souhami L">L Souhami</name></author><author><name sortKey="Grigsby, P" uniqKey="Grigsby P">P Grigsby</name></author><author><name sortKey="Gordon, W" uniqKey="Gordon W">W Gordon</name></author><author><name sortKey="Alberts, Ds" uniqKey="Alberts D">DS Alberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fabrini, Mg" uniqKey="Fabrini M">MG Fabrini</name></author><author><name sortKey="Gadducci, A" uniqKey="Gadducci A">A Gadducci</name></author><author><name sortKey="Perrone, F" uniqKey="Perrone F">F Perrone</name></author><author><name sortKey="Cosio, S" uniqKey="Cosio S">S Cosio</name></author><author><name sortKey="Laliscia, C" uniqKey="Laliscia C">C Laliscia</name></author><author><name sortKey="Pasqualetti, F" uniqKey="Pasqualetti F">F Pasqualetti</name></author><author><name sortKey="Grespi, S" uniqKey="Grespi S">S Grespi</name></author><author><name sortKey="Cionini, L" uniqKey="Cionini L">L Cionini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sehouli, J" uniqKey="Sehouli J">J Sehouli</name></author><author><name sortKey="Runnebaum, Ib" uniqKey="Runnebaum I">IB Runnebaum</name></author><author><name sortKey="Fotopoulou, C" uniqKey="Fotopoulou C">C Fotopoulou</name></author><author><name sortKey="Blohmer, U" uniqKey="Blohmer U">U Blohmer</name></author><author><name sortKey="Belau, A" uniqKey="Belau A">A Belau</name></author><author><name sortKey="Leber, H" uniqKey="Leber H">H Leber</name></author><author><name sortKey="Hanker, Lc" uniqKey="Hanker L">LC Hanker</name></author><author><name sortKey="Hartmann, W" uniqKey="Hartmann W">W Hartmann</name></author><author><name sortKey="Richter, R" uniqKey="Richter R">R Richter</name></author><author><name sortKey="Keyver Paik, Md" uniqKey="Keyver Paik M">MD Keyver-Paik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Ts" uniqKey="Lee T">TS Lee</name></author><author><name sortKey="Kang, Sb" uniqKey="Kang S">SB Kang</name></author><author><name sortKey="Kim, Yt" uniqKey="Kim Y">YT Kim</name></author><author><name sortKey="Park, Bj" uniqKey="Park B">BJ Park</name></author><author><name sortKey="Kim, Ym" uniqKey="Kim Y">YM Kim</name></author><author><name sortKey="Lee, Jm" uniqKey="Lee J">JM Lee</name></author><author><name sortKey="Kim, Sm" uniqKey="Kim S">SM Kim</name></author><author><name sortKey="Kim, Jh" uniqKey="Kim J">JH Kim</name></author><author><name sortKey="Kim, Kt" uniqKey="Kim K">KT Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Okazawa, M" uniqKey="Okazawa M">M Okazawa</name></author><author><name sortKey="Mabuchi, S" uniqKey="Mabuchi S">S Mabuchi</name></author><author><name sortKey="Isohashi, F" uniqKey="Isohashi F">F Isohashi</name></author><author><name sortKey="Suzuki, O" uniqKey="Suzuki O">O Suzuki</name></author><author><name sortKey="Yoshioka, Y" uniqKey="Yoshioka Y">Y Yoshioka</name></author><author><name sortKey="Sasano, T" uniqKey="Sasano T">T Sasano</name></author><author><name sortKey="Ohta, Y" uniqKey="Ohta Y">Y Ohta</name></author><author><name sortKey="Kamiura, S" uniqKey="Kamiura S">S Kamiura</name></author><author><name sortKey="Ogawa, K" uniqKey="Ogawa K">K Ogawa</name></author><author><name sortKey="Kimura, T" uniqKey="Kimura T">T Kimura</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Takekuma, M" uniqKey="Takekuma M">M Takekuma</name></author><author><name sortKey="Kasamatsu, Y" uniqKey="Kasamatsu Y">Y Kasamatsu</name></author><author><name sortKey="Kado, N" uniqKey="Kado N">N Kado</name></author><author><name sortKey="Kuji, S" uniqKey="Kuji S">S Kuji</name></author><author><name sortKey="Tanaka, A" uniqKey="Tanaka A">A Tanaka</name></author><author><name sortKey="Takahashi, N" uniqKey="Takahashi N">N Takahashi</name></author><author><name sortKey="Abe, M" uniqKey="Abe M">M Abe</name></author><author><name sortKey="Hirashima, Y" uniqKey="Hirashima Y">Y Hirashima</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Yy" uniqKey="Lee Y">YY Lee</name></author><author><name sortKey="Park, W" uniqKey="Park W">W Park</name></author><author><name sortKey="Huh, Sj" uniqKey="Huh S">SJ Huh</name></author><author><name sortKey="Yoon, A" uniqKey="Yoon A">A Yoon</name></author><author><name sortKey="Park, Jy" uniqKey="Park J">JY Park</name></author><author><name sortKey="Choi, Ch" uniqKey="Choi C">CH Choi</name></author><author><name sortKey="Kim, Tj" uniqKey="Kim T">TJ Kim</name></author><author><name sortKey="Lee, Jw" uniqKey="Lee J">JW Lee</name></author><author><name sortKey="Kim, Bg" uniqKey="Kim B">BG Kim</name></author><author><name sortKey="Bae, Ds" uniqKey="Bae D">DS Bae</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Trifiletti, Dm" uniqKey="Trifiletti D">DM Trifiletti</name></author><author><name sortKey="Swisher Mcclure, S" uniqKey="Swisher Mcclure S">S Swisher-McClure</name></author><author><name sortKey="Showalter, Tn" uniqKey="Showalter T">TN Showalter</name></author><author><name sortKey="Hegarty, Se" uniqKey="Hegarty S">SE Hegarty</name></author><author><name sortKey="Grover, S" uniqKey="Grover S">S Grover</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Colleoni, M" uniqKey="Colleoni M">M Colleoni</name></author><author><name sortKey="Bonetti, M" uniqKey="Bonetti M">M Bonetti</name></author><author><name sortKey="Coates, As" uniqKey="Coates A">AS Coates</name></author><author><name sortKey="Castiglione Gertsch, M" uniqKey="Castiglione Gertsch M">M Castiglione-Gertsch</name></author><author><name sortKey="Gelber, Rd" uniqKey="Gelber R">RD Gelber</name></author><author><name sortKey="Price, K" uniqKey="Price K">K Price</name></author><author><name sortKey="Rudenstam, Cm" uniqKey="Rudenstam C">CM Rudenstam</name></author><author><name sortKey="Lindtner, J" uniqKey="Lindtner J">J Lindtner</name></author><author><name sortKey="Collins, J" uniqKey="Collins J">J Collins</name></author><author><name sortKey="Thurlimann, B" uniqKey="Thurlimann B">B Thurlimann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arkenau, Ht" uniqKey="Arkenau H">HT Arkenau</name></author><author><name sortKey="Bermann, A" uniqKey="Bermann A">A Bermann</name></author><author><name sortKey="Rettig, K" uniqKey="Rettig K">K Rettig</name></author><author><name sortKey="Strohmeyer, G" uniqKey="Strohmeyer G">G Strohmeyer</name></author><author><name sortKey="Porschen, R" uniqKey="Porschen R">R Porschen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hofstetter, G" uniqKey="Hofstetter G">G Hofstetter</name></author><author><name sortKey="Concin, N" uniqKey="Concin N">N Concin</name></author><author><name sortKey="Braicu, I" uniqKey="Braicu I">I Braicu</name></author><author><name sortKey="Chekerov, R" uniqKey="Chekerov R">R Chekerov</name></author><author><name sortKey="Sehouli, J" uniqKey="Sehouli J">J Sehouli</name></author><author><name sortKey="Cadron, I" uniqKey="Cadron I">I Cadron</name></author><author><name sortKey="Van Gorp, T" uniqKey="Van Gorp T">T Van Gorp</name></author><author><name sortKey="Trillsch, F" uniqKey="Trillsch F">F Trillsch</name></author><author><name sortKey="Mahner, S" uniqKey="Mahner S">S Mahner</name></author><author><name sortKey="Ulmer, H" uniqKey="Ulmer H">H Ulmer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ryu, Hs" uniqKey="Ryu H">HS Ryu</name></author><author><name sortKey="Chun, M" uniqKey="Chun M">M Chun</name></author><author><name sortKey="Chang, Kh" uniqKey="Chang K">KH Chang</name></author><author><name sortKey="Chang, Hj" uniqKey="Chang H">HJ Chang</name></author><author><name sortKey="Lee, Jp" uniqKey="Lee J">JP Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kolb, Ba" uniqKey="Kolb B">BA Kolb</name></author><author><name sortKey="Buller, Re" uniqKey="Buller R">RE Buller</name></author><author><name sortKey="Connor, Jp" uniqKey="Connor J">JP Connor</name></author><author><name sortKey="Disaia, Pj" uniqKey="Disaia P">PJ DiSaia</name></author><author><name sortKey="Berman, Ml" uniqKey="Berman M">ML Berman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gunduz, N" uniqKey="Gunduz N">N Gunduz</name></author><author><name sortKey="Fisher, B" uniqKey="Fisher B">B Fisher</name></author><author><name sortKey="Saffer, Ea" uniqKey="Saffer E">EA Saffer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fisher, B" uniqKey="Fisher B">B Fisher</name></author><author><name sortKey="Gunduz, N" uniqKey="Gunduz N">N Gunduz</name></author><author><name sortKey="Saffer, Ea" uniqKey="Saffer E">EA Saffer</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28454573</article-id><article-id pub-id-type="pmc">5410059</article-id><article-id pub-id-type="publisher-id">3299</article-id><article-id pub-id-type="doi">10.1186/s12885-017-3299-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sang-Won</given-names></name><address><email>sangwon1014.kim@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2334-3316</contrib-id><name><surname>Chun</surname><given-names>Mison</given-names></name><address><phone>+82-31-219-5884</phone><email>chunm@ajou.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ryu</surname><given-names>Hee-Sug</given-names></name><address><email>hsryu@ajou.ac.kr</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Suk-Joon</given-names></name><address><email>drchang@ajou.ac.kr</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kong</surname><given-names>Tae Wook</given-names></name><address><email>twconf@aumc.ac.kr</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Young-Taek</given-names></name><address><email>ohyoung@ajou.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>Seung Hee</given-names></name><address><email>shkang6511@naver.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Radiation Oncology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8674 9741</institution-id><institution-id institution-id-type="GRID">grid.411143.2</institution-id><institution>Department of Radiation Oncology,</institution><institution>Konyang University College of Medicine,</institution></institution-wrap>158 Gwanjeodong-ro, Seo-gu, Daejeon, 35365 Republic of Korea</aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0532 3933</institution-id><institution-id institution-id-type="GRID">grid.251916.8</institution-id><institution>Department of Obstetrics and Gynecology,</institution><institution>Ajou University School of Medicine,</institution></institution-wrap>164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499 Republic of Korea</aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5112</institution-id><institution-id institution-id-type="GRID">grid.411612.1</institution-id><institution>Department of Radiation Oncology, Ilsan Paik Hospital,</institution><institution>Inje University School of Medicine,</institution></institution-wrap>170 Juhwa-ro, Ilsanseo-gu, Goyang, Gyeonggi-do 10380 Republic of Korea</aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>297</elocation-id><history><date date-type="received"><day>17</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>© The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The aim of the present study was to investigate the long-term survival outcomes and toxicities associated with our experienced early administration of adjuvant concurrent chemoradiotherapy (CCRT).</p></sec><sec><title>Methods</title><p>Ninety-eight patients with pelvic lymph node metastasis, positive resection margin, and/or parametrial invasion who received adjuvant CCRT between 1995 and 2011 were analyzed retrospectively. The first cycle of platinum-based adjuvant chemotherapy was initiated within 2–3 weeks after surgery (median, 12 days) and continued every 4 weeks for a total of 4 cycles. Adjuvant radiotherapy was performed during the second and third cycles of chemotherapy.</p></sec><sec><title>Results</title><p>After a median follow-up period of 119 months for survivors, 13 patients (13.3%) experienced recurrence and 11 patients died of cancer during the follow-up period. The 5-year recurrence-free survival and cancer specific survival rates were 87.6% and 90.6%, respectively. Ninety-four patients (95.9%) received ≥3 cycles of chemotherapy. Total radiation dose of ≥45 Gy was delivered in 91 patients (92.9%). Grade 3–4 hematologic and gastrointestinal toxicities developed in 37 (37.8%) and 14 (14.3%) patients during CCRT, respectively.</p></sec><sec><title>Conclusion</title><p>The present study confirmed the long-term safety and encouraging survival outcomes of early administration of adjuvant CCRT, suggesting the benefits of early time to initiation of adjuvant treatments.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Uterine cervical neoplasm</kwd><kwd>Adjuvant chemoradiotherapy</kwd><kwd>Time to treatment</kwd><kwd>Treatment outcome</kwd><kwd>Long term adverse effects</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>The primary treatment for International Federation of Gynecology and Obstetrics (FIGO) stage IA2–IIA uterine cervical cancer is either radical hysterectomy or external beam radiotherapy with or without concurrent platinum-based chemotherapy [<xref ref-type="bibr" rid="CR1">1</xref>]. Although both treatment modalities have similar survival rates, radical hysterectomy is particularly preferred in some young patients because of thorough evaluation of pelvic lymph nodes, prevention of premature and avoidance of radiation-induced late toxicities. However, a considerable patient with certain adverse pathologic factors have a high possibility of recurrence despite they undergo radical surgery [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Of these, parametrial invasion, positive resection margin, and pelvic lymph node metastasis were classified as high-risk.</p><p>Adjuvant radiotherapy significantly improved 2-year recurrence-free rate in patients with intermediate risk factors compared with no further treatment [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. However, in high-risk patients, adjuvant radiotherapy alone had a limited role in locoregional control without any survival benefits [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In 2000, the Southwest Oncology Group (SWOG), Gynecologic Oncology Group (GOG), and Radiation Therapy Oncology Group (RTOG) reported a collaborative phase III prospective randomized trial comparing the survival outcomes between adjuvant radiotherapy alone and adjuvant concurrent chemoradiotherapy (CCRT) in high-risk, early stage uterine cervical cancer patients [<xref ref-type="bibr" rid="CR13">13</xref>]. This trial (GOG 109/SWOG 8797/RTOG 91–12) demonstrated the beneficial effects of the concomitant administration of platinum-based chemotherapy on the survival rates, as well as the disadvantage of increased treatment-related toxicities.</p><p>Over the last decade, several studies addressing various settings of adjuvant CCRT reported similar outcomes, with a 5-year recurrence free survival rate of 70–80% and a 5-year overall survival rate of 80–85% [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. In all the previous studies, the first cycle of adjuvant chemotherapy was usually initiated 4–6 weeks after surgery and adjuvant radiotherapy was performed concurrently with the first cycle of adjuvant chemotherapy.</p><p>Early start of adjuvant treatments showed potential for improvement of survival outcomes in breast cancer [<xref ref-type="bibr" rid="CR21">21</xref>], colon cancer [<xref ref-type="bibr" rid="CR22">22</xref>] and ovarian cancer [<xref ref-type="bibr" rid="CR23">23</xref>]. On the other hand, there have been no related literatures in cervical cancer. We previously reported the feasibility and promising results of the early administration of adjuvant CCRT, with a 5-year progression-free survival rate of 88.7% and a 5-yearoverall survival rate of 96.7% [<xref ref-type="bibr" rid="CR24">24</xref>]. However, small sample sizes and short follow-up duration remained limitations to the study. In the present study, we reported the long-term outcomes and toxicities associated with the early administration of adjuvant CCRT for high-risk, early stage uterine cervical cancer.</p></sec><sec id="Sec2"><title>Methods</title><p>The present study was approved by the Institutional Review Board of Ajou University School of Medicine with an exemption from informed consent. We reviewed the medical records of all high-risk, early stage (FIGO IA2–IIA1) uterine cervical cancer patients who received adjuvant CCRT at our institution between 1995 and 2011. The exclusion criteria were the following: 1) class I or II radical hysterectomy, 2) small cell or neuroendocrine carcinoma, 3) para-aortic lymph node metastasis, 4) history of neoadjuvant chemotherapy and 5) initiation of adjuvant CCRT more than 3 weeks after surgery.</p><p>We performed a previously described treatment scheme [<xref ref-type="bibr" rid="CR24">24</xref>]. In detail, after baseline staging work-ups, all patients underwent class III radical hysterectomy with bilateral pelvic lymphadenectomy and para-aortic lymph node sampling or dissection. The first cycle of adjuvant chemotherapy was initiated within 2–3 weeks after surgery. The most common treatment regimen was cisplatin (70 mg/m<sup>2</sup>) plus 5-fluorouracil (1000 mg/m<sup>2</sup>/day) (<italic>n</italic> = 90). Other regimens included paclitaxel (175 mg/m<sup>2</sup>) combined with either cisplatin or carboplatin (area under curve of 5) (<italic>n</italic> = 8). The combination chemotherapy regimens were administered every 4 weeks for a total of 4 cycles.</p><p>Adjuvant radiotherapy was initiated during the second course of chemotherapy. Whole-pelvic irradiation was given with a median total dose of 45 Gy in 25 fractions using a traditional four-field box technique. An additional boost of 5.4–10.8 Gy was delivered to the risky area in patients with parametrial invasion or positive lateral resection margins. Patients with positive common iliac lymph nodes received elective para-aortic irradiation with a median total dose of 44.2 Gy in 26 fractions. In patients with positive vaginal cuff resection margins, vaginal brachytherapy administered once or twice with a fraction size of 4–5 Gy after completion of external beam radiotherapy was indicated.</p><p>Acute and late treatment-related toxicities were evaluated based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.02. Adjuvant CCRT was interrupted if any grade ≥ 3 toxicities occurred. The treatment was recommenced after any signs or symptoms of severe toxicities subsided.</p><sec id="Sec3"><title>Statistical analysis</title><p>The primary endpoints of the present study were the 5-year recurrence-free survival (RFS) and cervical cancer-specific survival (CSS) rates. The secondary endpoints were the 5-year locoregional recurrence free survival (LRRFS), distant metastasis-free (DMFS) and overall survival (OS) rates. All endpoints were measured from the date of radical hysterectomy and were calculated using the Kaplan–Meier method. A univariate analysis was performed with log-rank test. A multivariate analysis using factors with <italic>p</italic> value of <0.10 in univariate analysis was performed using the Cox proportional hazards model through backward stepwise elimination. All statistical analyses were performed using the R software version 3.2.4 (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org">https://cran.r-project.org</ext-link>/). A two-sided <italic>p</italic> value of <0.05 was considered statistically significant.</p></sec></sec><sec id="Sec4"><title>Results</title><sec id="Sec5"><title>Patient characteristics</title><p>Between 1995 and 2001, a total of 98 patients received early administration of adjuvant CCRT within 2–3 weeks after radical hysterectomy. The patient characteristics are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>. The median age was 47 years (range, 26 to 71 years). Approximately two-thirds of patients (<italic>n</italic> = 66) had a single risk factor. The measurement of serum squamous cell carcinoma antigen before surgery was available in 96 patients, with a median value of 1.5 ng/mL (range, 0.1 to 43.9).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th>No. of patients (%)</th></tr></thead><tbody><tr><td>Age</td><td>median, 47</td></tr><tr><td>Clinical FIGO stage</td><td></td></tr><tr><td> IA2</td><td>1 (1.0)</td></tr><tr><td> IB1</td><td>71 (72.5)</td></tr><tr><td> IB2</td><td>24 (24.5)</td></tr><tr><td> IIA</td><td>2 (2.0)</td></tr><tr><td>Histology</td><td></td></tr><tr><td> Squamous cell carcinoma</td><td>74 (75.5)</td></tr><tr><td> non-squamous cell carcinoma</td><td>24 (24.5)</td></tr><tr><td>SCC Ag</td><td></td></tr><tr><td> ≤ 2 ng/ml</td><td>50 (51.0)</td></tr><tr><td> > 2 ng/ml</td><td>46 (47.0)</td></tr><tr><td> unknown</td><td>2 (2.0)</td></tr><tr><td>Tumor size</td><td></td></tr><tr><td> ≤ 4 cm</td><td>50 (51.0)</td></tr><tr><td> > 4 cm</td><td>42 (42.9)</td></tr><tr><td> unknown</td><td>6 (6.1)</td></tr><tr><td>Deep stromal invasion</td><td></td></tr><tr><td> absent</td><td>23 (23.5)</td></tr><tr><td> present</td><td>75 (76.5)</td></tr><tr><td>Lymphovascular space invasion</td><td></td></tr><tr><td> absent</td><td>4 (4.1)</td></tr><tr><td> present</td><td>92 (93.9)</td></tr><tr><td> unknown</td><td>2 (2.0)</td></tr><tr><td>Parametrial invasion</td><td></td></tr><tr><td> negative</td><td>84 (85.7)</td></tr><tr><td> positive</td><td>14 (14.3)</td></tr><tr><td>Resection margin</td><td></td></tr><tr><td> negative</td><td>56 (57.1)</td></tr><tr><td> close (<5 mm)</td><td>9 (9.2)</td></tr><tr><td> positive</td><td>33 (33.7)</td></tr><tr><td>Pelvic lymph node metastasis</td><td></td></tr><tr><td> negative</td><td>19 (19.4)</td></tr><tr><td> positive</td><td>79 (80.6)</td></tr><tr><td>LNR</td><td></td></tr><tr><td> < 0.25</td><td>87 (88.8)</td></tr><tr><td> ≥ 0.25</td><td>11 (10.2)</td></tr><tr><td>No. of high risk factor</td><td></td></tr><tr><td> 1</td><td>66 (67.3)</td></tr><tr><td> 2</td><td>27 (27.6)</td></tr><tr><td> 3</td><td>5 (5.1)</td></tr></tbody></table><table-wrap-foot><p><italic>FIGO</italic> International federation of gynecology and obstetrics, <italic>SCC Ag</italic> squamous cell carcinoma antigen, <italic>LNR</italic>, lymph node ratio</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec6"><title>Treatment compliance</title><p>The median interval between radical hysterectomy and initiation of adjuvant chemotherapy in entire patients was 12 days (range, 8 to 21 days). The second cycle of adjuvant chemotherapy was delayed for >1 week in 6 patients owing to abscess development (<italic>n</italic> = 1), slow recovery from chemotherapy-related toxicities (<italic>n</italic> = 3), and personal reasons (<italic>n</italic> = 2). Ninety-four patients (95.9%) received ≥3 cycles of adjuvant chemotherapy. Chemotherapy was terminated in the remaining 4 patients before the third cycle, owing to treatment intolerability.</p><p>The median interval between surgery and the initiation of radiotherapy was 41 days (range, 28 to 70 days). Ninety-one patients (92.9%) received a total radiation dose of ≥45 Gy. The interruption of radiotherapy for >2 weeks because of treatment-related toxicities (<italic>n</italic> = 2) or poor compliance (<italic>n</italic> = 5) occurred in 7 patients.</p></sec><sec id="Sec7"><title>Survival rate</title><p>The median follow-up period was 119 months (range, 55 to 255 months) for all survivors. Recurrences occurred in 13 patients (13.3%); 4 (4.1%) of which were isolated locoregional recurrences, 4 (4.1%) were simultaneous locoregional recurrences and distant metastases, and 5 (5.1%) were distant metastases. Of these, 2 patients with lung metastasis developed 34 and 66 months after radical hysterectomy attained no evidence of disease after salvage metastatectomy.</p><p>The 5-year LRRFS, DMFS and RFS rates were 91.5% (95% confidence interval [CI], 86.0–97.3%), 90.6% (95% CI, 84.9–96.6%), and 87.6% (95% CI, 81.3–94.4%), respectively (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). In univariate analysis, the number of positive pelvic lymph nodes ≥3 (<italic>p</italic> = 0.021), and lymph node ratio ≥ 0.25 (<italic>p</italic> = 0.018) were significantly associated with poor RFS. Multivariate analysis revealed the number of positive lymph nodes ≥3 as a significant prognostic factor (hazard ratio [HR], 3.179; 95% CI, 1.066–9.477; <italic>p</italic> = 0.038) (Table <xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Kaplan-Meier curve of recurrence-free survival for all patients (<italic>dotted line</italic>, 95% confidence interval)</p></caption><graphic xlink:href="12885_2017_3299_Fig1_HTML" id="MO1"></graphic></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Univariate and multivariate analyses for RFS and CSS</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="5">RFS</th><th colspan="5">CSS</th></tr><tr><th>variables</th><th>5 yr. rate</th><th><italic>p</italic> value</th><th>HR</th><th>95% CI</th><th><italic>p</italic> value</th><th>5 yr. rate</th><th><italic>p</italic> value</th><th>HR</th><th>95% CI</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>size >4 cm</td><td align="center"></td><td char="." align="char">0.304</td><td></td><td></td><td></td><td align="center"></td><td char="." align="char">0.073</td><td>2.781</td><td>0.710–10.990</td><td>0.142</td></tr><tr><td> no</td><td>92.0</td><td></td><td></td><td></td><td></td><td>93.9</td><td></td><td></td><td></td><td></td></tr><tr><td> yes</td><td>83.1</td><td></td><td></td><td></td><td></td><td>87.9</td><td></td><td></td><td></td><td></td></tr><tr><td>SCC Ag</td><td align="center"></td><td char="." align="char">0.611</td><td></td><td></td><td></td><td align="center"></td><td char="." align="char">0.904</td><td></td><td></td><td></td></tr><tr><td> ≤ 2 ng/mL</td><td>88.0</td><td></td><td></td><td></td><td></td><td>89.9</td><td></td><td></td><td></td><td></td></tr><tr><td> > 2 ng/mL</td><td>86.9</td><td></td><td></td><td></td><td></td><td>91.2</td><td></td><td></td><td></td><td></td></tr><tr><td>DSI</td><td align="center"></td><td char="." align="char">0.985</td><td></td><td></td><td></td><td align="center"></td><td char="." align="char">0.778</td><td></td><td></td><td></td></tr><tr><td> absent</td><td>86.4</td><td></td><td></td><td></td><td></td><td>90.7</td><td></td><td></td><td></td><td></td></tr><tr><td> present</td><td>87.9</td><td></td><td></td><td></td><td></td><td>90.6</td><td></td><td></td><td></td><td></td></tr><tr><td>LVSI</td><td align="center"></td><td char="." align="char">0.671</td><td></td><td></td><td></td><td align="center"></td><td char="." align="char">0.720</td><td></td><td></td><td></td></tr><tr><td> absent</td><td>100.0</td><td></td><td></td><td></td><td></td><td>100.0</td><td></td><td></td><td></td><td></td></tr><tr><td> present</td><td>86.9</td><td></td><td></td><td></td><td></td><td>90.1</td><td></td><td></td><td></td><td></td></tr><tr><td>PM invasion</td><td align="center"></td><td char="." align="char">0.145</td><td></td><td></td><td></td><td align="center"></td><td char="." align="char">0.196</td><td></td><td></td><td></td></tr><tr><td> absent</td><td>85.7</td><td></td><td></td><td></td><td></td><td>89.2</td><td></td><td></td><td></td><td></td></tr><tr><td> present</td><td>100.0</td><td></td><td></td><td></td><td></td><td>100.0</td><td></td><td></td><td></td><td></td></tr><tr><td>RM</td><td align="center"></td><td char="." align="char">0.052</td><td char="." align="char">2.868</td><td char="–" align="char">0.881–9.333</td><td char="." align="char">0.080</td><td align="center"></td><td char="." align="char">0.132</td><td></td><td></td><td></td></tr><tr><td> clear</td><td>92.8</td><td></td><td></td><td></td><td></td><td>92.7</td><td></td><td></td><td></td><td></td></tr><tr><td> close or positive</td><td>81.0</td><td></td><td></td><td></td><td></td><td>88.0</td><td></td><td></td><td></td><td></td></tr><tr><td>LN metastasis</td><td align="center"></td><td char="." align="char">0.664</td><td></td><td></td><td></td><td align="center"></td><td char="." align="char">0.932</td><td></td><td></td><td></td></tr><tr><td> absent</td><td>88.8</td><td></td><td></td><td></td><td></td><td>88.2</td><td></td><td></td><td></td><td></td></tr><tr><td> present</td><td>87.3</td><td></td><td></td><td></td><td></td><td>91.1</td><td></td><td></td><td></td><td></td></tr><tr><td>No. of positive LN</td><td align="center"></td><td char="." align="char">0.021</td><td char="." align="char">3.179</td><td char="–" align="char">1.066–9.477</td><td char="." align="char">0.038</td><td align="center"></td><td char="." align="char">0.005</td><td char="." align="char">4.004</td><td char="–" align="char">1.130–14.195</td><td char="." align="char">0.032</td></tr><tr><td> 0–2</td><td>92.8</td><td></td><td></td><td></td><td></td><td>94.5</td><td></td><td></td><td></td><td></td></tr><tr><td> ≥ 3</td><td>74.1</td><td></td><td></td><td></td><td></td><td>81.5</td><td></td><td></td><td></td><td></td></tr><tr><td>LNR</td><td align="center"></td><td char="." align="char">0.018</td><td char="." align="char">2.330</td><td char="–" align="char">0.611–8.879</td><td char="." align="char">0.215</td><td align="center"></td><td char="." align="char">0.011</td><td char="." align="char">1.740</td><td char="–" align="char">0.391–7.740</td><td char="." align="char">0.467</td></tr><tr><td> < 0.25</td><td>90.7</td><td></td><td></td><td></td><td></td><td>91.8</td><td></td><td></td><td></td><td></td></tr><tr><td> ≥ 0.25</td><td>63.6</td><td></td><td></td><td></td><td></td><td>81.8</td><td></td><td></td><td></td><td></td></tr><tr><td>No. of risk factors</td><td align="center"></td><td char="." align="char">0.299</td><td></td><td></td><td></td><td align="center"></td><td char="." align="char">0.345</td><td></td><td></td><td></td></tr><tr><td> 1</td><td>90.8</td><td></td><td></td><td></td><td></td><td>90.7</td><td></td><td></td><td></td><td></td></tr><tr><td> 2–3</td><td>81.3</td><td></td><td></td><td></td><td></td><td>90.6</td><td></td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p><italic>RFS</italic> recurrence free survival rate, <italic>CSS</italic> cancer specific survival rate, <italic>HR</italic> hazard ratio, <italic>CI</italic> confidence interval, <italic>SCC Ag</italic> squamous cell carcinoma antigen, <italic>DSI</italic> deep stromal invasion, <italic>LVSI</italic> lymphovascular space invasion, <italic>PM</italic> parametrium, <italic>RM</italic> resection margin, <italic>LN</italic> lymph node, <italic>LNR</italic> lymph node ratio</p></table-wrap-foot></table-wrap></p><p>At the last follow-up, 11 patients died of cancer progression and 4 died of intercurrent causes. The 5-year CSS and OS were 90.6% (95% CI, 85.0–96.7%) and 88.7% (95% CI, 82.7–95.2%), respectively (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Univariate analysis identified the number of positive pelvic lymph nodes ≥3 (<italic>p</italic> = 0.005) and lymph node ratio ≥ 0.25 (<italic>p</italic> = 0.011) as the significant risk factors for CSS. In multivariate analysis, the number of positive pelvic lymph nodes ≥3 (HR, 4.004; 95% CI, 1.130–14.195; <italic>p</italic> = 0.032) was the only prognostic factor for CSS (Table <xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan-Meier curve of cancer-specific survival for all patients (<italic>dotted line</italic>, 95% confidence interval)</p></caption><graphic xlink:href="12885_2017_3299_Fig2_HTML" id="MO2"></graphic></fig></p></sec><sec id="Sec8"><title>Toxicities</title><p>Hematologic toxicities of CTCAE grade 3–4 occurred in 37 patients (37.8%; Table <xref rid="Tab3" ref-type="table">3</xref>). Of these, febrile neutropenia developed in 2 patients (2.0%) and they recovered after antibiotic therapy. Fourteen patients (14.3%) developed grade ≥ 3 gastrointestinal toxicities during adjuvant CCRT. Of these, 3 patients (3.1%) developed grade 4 small bowel obstruction and they recovered fully after successful surgical intervention. One patient died of panperitonitis due to small bowel perforation 7 years after the completion of adjuvant CCRT.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Grade 3 or more Treatment-related toxicities</p></caption><table frame="hsides" rules="groups"><thead><tr><th>variables</th><th>Percent</th></tr></thead><tbody><tr><td>Hematologic</td><td align="center"></td></tr><tr><td> leukopenia</td><td>36.5</td></tr><tr><td> neutropenia</td><td>11.5</td></tr><tr><td> anemia</td><td>8.7</td></tr><tr><td> thrombocytopenia</td><td>1.0</td></tr><tr><td>Gastrointestinal</td><td align="center"></td></tr><tr><td> anorexia</td><td>1.9</td></tr><tr><td> nausea/vomiting</td><td>1.9</td></tr><tr><td> diarrhea</td><td>6.7</td></tr><tr><td> proctitis</td><td>1.0</td></tr><tr><td> small bowel obstruction</td><td>4.8</td></tr><tr><td>Lymphedema</td><td>1.0</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec9"><title>Discussion</title><p>Consistent with the results of our previous study [<xref ref-type="bibr" rid="CR24">24</xref>], the present study demonstrated the safety and encouraging treatment outcomes of the early administration of adjuvant CCRT.</p><p>In the current clinical practice, adjuvant CCRT for high-risk, early stage uterine cervical cancer is usually allowed to initiate 4–6 weeks after radical hysterectomy, providing time for wound healing. Therefore, it can be assumed that early initiation of adjuvant CCRT within 2–3 weeks from radical surgery potentially causes delayed wound healing. However, Kolb et al. reported that early initiation of adjuvant chemotherapy was not related to any increase in wound complications after cytoreductive surgery for ovarian cancer [<xref ref-type="bibr" rid="CR25">25</xref>]. In the present study, the incidence of postoperative morbidities was similar to that of previous studies, confirming the safety of early administration of adjuvant CCRT [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. The timely initiation of the second course of adjuvant chemotherapy and radiotherapy in the majority of patients (95.8%) supported this finding.</p><p>Early administration of adjuvant CCRT has another possible concern of increasing treatment-related toxicities because of inadequate recovery from radical surgery. However, the incidence rates of grade 3–4 treatment-related toxicities in the present study were comparable to those reported by the previous studies [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. We did not observe any late toxicities related to early administration of adjuvant CCRT. Thus, the present study reconfirmed the safety of the early administration of adjuvant CCRT with long-term follow-up.</p><p>In the present study, the 5-year RFS and CSS rates were 87.6% and 90.6%, respectively. An indirect comparison with previous studies showed that the survival outcomes in the present study appeared to be more favorable [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. We used chemotherapeutic regimen based on contemporary guidelines and conventional radiotherapy. The major discrimination between the present study and previous studies was the time to initiation of adjuvant treatments. Therefore, early administration of adjuvant CCRT might have potential for improvement of adjuvant treatment outcomes.</p><p>The benefit of early administration of adjuvant CCRT could be explained by the properties of chemotherapeutic agents. In a preclinical experiment, Gunduz et al. observed that the surgical removal of tumor converted dormant tumor cells into rapidly proliferating ones [<xref ref-type="bibr" rid="CR26">26</xref>]. In a subsequent study, they demonstrated that long interval between surgical removal of primary tumor and administration of chemotherapy attenuated the cytotoxic effects of the drug, manifested by a decrease in the proliferative index of tumor cells and a gradual increase in the total tumor volume over time [<xref ref-type="bibr" rid="CR27">27</xref>]. Considering the high sensitivity of the chemotherapeutic agents to rapidly proliferating cells and lower tumor burden, the immediate administration of adjuvant treatments after surgery as possible could maximize their efficacy.</p><p>In addition, early administration of adjuvant CCRT contributed to improved survival rates in a different way. The major concern of adjuvant CCRT for high-risk, early stage uterine cervical cancer was poor compliance due to synergistic effects of each treatment-related toxicities. Approximately a quarter of patients ceased further chemotherapy before the third cycle of chemotherapy in the GOG 109/SWOG 8797/RTOG 91–12 trial. Furthermore, patients who discontinued further chemotherapy after the completion of radiotherapy had significantly lower survival rates than those who received ≥3 cycles of chemotherapy (<italic>p</italic> = 0.03 for both progression-free and overall survival), demonstrating the favorable effect of a higher number of chemotherapy courses. Early administration of adjuvant CCRT provided a countermeasure through the delivery of adjuvant radiotherapy at the second cycle of adjuvant chemotherapy without deferring the time to initiation of irradiation (median, 41 days). Therefore, ≥3 cycles of chemotherapy were guaranteed in the majority of the patients even though further chemotherapy was not administered following the completion of radiotherapy at the patients’ discretion. As mentioned above, the majority of patients (95.9%) in the present study received ≥3 cycles of chemotherapy and the survival outcomes were comparable with those who received ≥3 cycles of chemotherapy in the GOG 109/SWOG 8797/RTOG 91–12 trial. Based on this finding, the higher number of chemotherapy courses owing to early administration of adjuvant CCRT might contribute to the improvement of adjuvant treatment outcomes.</p><p>The present study had several limitations. First, the sample size was not large enough to draw definite conclusions. Second, the present study might have selection bias because of its retrospective nature. Finally, the details of adjuvant treatment were heterogeneous in the minority of patients. However, given the similar survival rates among different chemotherapeutic regimen in previous studies and few evidence that demonstrated survival benefit by vaginal brachytherapy in the adjuvant setting of cervical cancer, it is unlikely that heterogeneities in the treatment approach influenced treatment outcomes.</p></sec><sec id="Sec10"><title>Conclusion</title><p>In summary, the present study demonstrated encouraging adjuvant treatment outcomes in high-risk cervical cancer patients, possibly owing to early time to initiation of adjuvant CCRT. The treatment compliance and toxicities were also at the comparable levels. Therefore, the present study might suggest a direction for further improvement of adjuvant treatment for high-risk, early stage uterine cervical cancer. Whether this treatment strategy is effective in only selected patients, further studies with a prospective design are warranted.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CCRT</term><def><p>Concurrent chemoradiotherapy</p></def></def-item><def-item><term>CI</term><def><p>Confidence interval</p></def></def-item><def-item><term>CSS</term><def><p>Cancer-specific survival</p></def></def-item><def-item><term>CTCAE</term><def><p>Common Terminology Criteria for Adverse Events</p></def></def-item><def-item><term>DMFS</term><def><p>Distant metastasis-free survival</p></def></def-item><def-item><term>FIGO</term><def><p>International Federation of Gynecology and Obstetrics</p></def></def-item><def-item><term>GOG</term><def><p>Gynecologic Oncology Group</p></def></def-item><def-item><term>HR</term><def><p>Hazard ratio</p></def></def-item><def-item><term>LRRFS</term><def><p>Loco-regional recurrence free survival</p></def></def-item><def-item><term>OS</term><def><p>Overall survival</p></def></def-item><def-item><term>RFS</term><def><p>Recurrence-free survival</p></def></def-item><def-item><term>RTOG</term><def><p>Radiation Therapy Oncology Group</p></def></def-item><def-item><term>SWOG</term><def><p>Southwest Oncology Group</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>None.</p><sec id="FPar1"><title>Funding</title><p>None.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>All the relevant data supporting the conclusions are presented within manuscript.</p></sec><sec id="FPar3"><title>Author’s contributions</title><p>Study concepts and design: MC, Y-TO, S-WK; Data acquisition: MC, HSR, SJC, TWK, SHK; Analysis and interpretation of data: MC, Y-TO, S-WK; Drafting of manuscript: S-WK, MC; Approval of final manuscripts: all authors.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The present study was approved by the Institutional Review Board of Ajou University School of Medicine with an exemption from informed consent (AJIRB–MED–MDB–16–068).</p></sec><sec id="FPar7"><title>Publisher’s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landoni</surname><given-names>F</given-names></name><name><surname>Maneo</surname><given-names>A</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Placa</surname><given-names>F</given-names></name><name><surname>Milani</surname><given-names>R</given-names></name><name><surname>Perego</surname><given-names>P</given-names></name><name><surname>Favini</surname><given-names>G</given-names></name><name><surname>Ferri</surname><given-names>L</given-names></name><name><surname>Mangioni</surname><given-names>C</given-names></name></person-group><article-title>Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer</article-title><source>Lancet</source><year>1997</year><volume>350</volume><issue>9077</issue><fpage>535</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(97)02250-2</pub-id><pub-id pub-id-type="pmid">9284774</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Okumura</surname><given-names>M</given-names></name></person-group><article-title>Prognostic significance of parametrial extension in patients with cervical carcinoma Stages IB, IIA, and IIB. A study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation</article-title><source>Cancer</source><year>1984</year><volume>54</volume><issue>8</issue><fpage>1714</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19841015)54:8<1714::AID-CNCR2820540838>3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">6478409</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>RD</given-names></name><name><surname>Soong</surname><given-names>SJ</given-names></name><name><surname>Kinney</surname><given-names>WK</given-names></name><name><surname>Reid</surname><given-names>GC</given-names></name><name><surname>Schray</surname><given-names>MF</given-names></name><name><surname>Podratz</surname><given-names>KC</given-names></name><name><surname>Morley</surname><given-names>GW</given-names></name><name><surname>Shingleton</surname><given-names>HM</given-names></name></person-group><article-title>Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix</article-title><source>Gynecol Oncol</source><year>1989</year><volume>35</volume><issue>2</issue><fpage>130</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/0090-8258(89)90029-2</pub-id><pub-id pub-id-type="pmid">2807001</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>AF</given-names><suffix>Jr</suffix></name><name><surname>Elliott</surname><given-names>N</given-names></name><name><surname>Kosloff</surname><given-names>C</given-names></name><name><surname>Hoskins</surname><given-names>WJ</given-names></name><name><surname>Lewis</surname><given-names>JL</given-names><suffix>Jr</suffix></name></person-group><article-title>Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix</article-title><source>Gynecol Oncol</source><year>1989</year><volume>33</volume><issue>1</issue><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/0090-8258(89)90598-2</pub-id><pub-id pub-id-type="pmid">2703164</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevin</surname><given-names>BU</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>Nadji</surname><given-names>M</given-names></name><name><surname>Koechli</surname><given-names>OR</given-names></name><name><surname>Averette</surname><given-names>HE</given-names></name></person-group><article-title>Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis</article-title><source>Cancer</source><year>1996</year><volume>78</volume><issue>7</issue><fpage>1438</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19961001)78:7<1438::AID-CNCR10>3.0.CO;2-0</pub-id><pub-id pub-id-type="pmid">8839549</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zreik</surname><given-names>TG</given-names></name><name><surname>Chambers</surname><given-names>JT</given-names></name><name><surname>Chambers</surname><given-names>SK</given-names></name></person-group><article-title>Parametrial involvement, regardless of nodal status: a poor prognostic factor for cervical cancer</article-title><source>Obstet Gynecol</source><year>1996</year><volume>87</volume><issue>5 Pt 1</issue><fpage>741</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/0029-7844(96)00026-9</pub-id><pub-id pub-id-type="pmid">8677078</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estape</surname><given-names>RE</given-names></name><name><surname>Angioli</surname><given-names>R</given-names></name><name><surname>Madrigal</surname><given-names>M</given-names></name><name><surname>Janicek</surname><given-names>M</given-names></name><name><surname>Gomez</surname><given-names>C</given-names></name><name><surname>Penalver</surname><given-names>M</given-names></name><name><surname>Averette</surname><given-names>H</given-names></name></person-group><article-title>Close vaginal margins as a prognostic factor after radical hysterectomy</article-title><source>Gynecol Oncol</source><year>1998</year><volume>68</volume><issue>3</issue><fpage>229</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1006/gyno.1998.4960</pub-id><pub-id pub-id-type="pmid">9570971</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>KJ</given-names></name><name><surname>Park</surname><given-names>KR</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Moon</surname><given-names>HS</given-names></name><name><surname>Ju</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><etal></etal></person-group><article-title>Prognostic analysis of uterine cervical cancer treated with postoperative radiotherapy: importance of positive or close parametrial resection margin</article-title><source>Radiat Oncol J</source><year>2015</year><volume>33</volume><issue>2</issue><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.3857/roj.2015.33.2.109</pub-id><pub-id pub-id-type="pmid">26157680</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedlis</surname><given-names>A</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Rotman</surname><given-names>MZ</given-names></name><name><surname>Lentz</surname><given-names>SS</given-names></name><name><surname>Muderspach</surname><given-names>LI</given-names></name><name><surname>Zaino</surname><given-names>RJ</given-names></name></person-group><article-title>A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study</article-title><source>Gynecol Oncol</source><year>1999</year><volume>73</volume><issue>2</issue><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1006/gyno.1999.5387</pub-id><pub-id pub-id-type="pmid">10329031</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotman</surname><given-names>M</given-names></name><name><surname>Sedlis</surname><given-names>A</given-names></name><name><surname>Piedmonte</surname><given-names>MR</given-names></name><name><surname>Bundy</surname><given-names>B</given-names></name><name><surname>Lentz</surname><given-names>SS</given-names></name><name><surname>Muderspach</surname><given-names>LI</given-names></name><name><surname>Zaino</surname><given-names>RJ</given-names></name></person-group><article-title>A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>65</volume><issue>1</issue><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.10.019</pub-id><pub-id pub-id-type="pmid">16427212</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>CP</given-names></name><name><surname>Shingleton</surname><given-names>HM</given-names></name><name><surname>Austin</surname><given-names>JM</given-names></name><name><surname>Averette</surname><given-names>HE</given-names></name><name><surname>Girtanner</surname><given-names>RE</given-names></name><name><surname>Webb</surname><given-names>MJ</given-names></name><name><surname>Masterson</surname><given-names>JG</given-names></name><name><surname>Morley</surname><given-names>GW</given-names></name></person-group><article-title>Is pelvic radiation beneficial in the postoperative management of stage Ib squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy?: A report from the presidential panel at the 1979 Annual Meeting of the Society of Gynecologic Oncologists</article-title><source>Gynecol Oncol</source><year>1980</year><volume>10</volume><issue>1</issue><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/0090-8258(80)90071-2</pub-id><pub-id pub-id-type="pmid">7399327</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinney</surname><given-names>WK</given-names></name><name><surname>Alvarez</surname><given-names>RD</given-names></name><name><surname>Reid</surname><given-names>GC</given-names></name><name><surname>Schray</surname><given-names>MF</given-names></name><name><surname>Soong</surname><given-names>SJ</given-names></name><name><surname>Morley</surname><given-names>GW</given-names></name><name><surname>Podratz</surname><given-names>KC</given-names></name><name><surname>Shingleton</surname><given-names>HM</given-names></name></person-group><article-title>Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study</article-title><source>Gynecol Oncol</source><year>1989</year><volume>34</volume><issue>3</issue><fpage>258</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/0090-8258(89)90156-X</pub-id><pub-id pub-id-type="pmid">2767517</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>WA</given-names><suffix>3rd</suffix></name><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Barrett</surname><given-names>RJ</given-names><suffix>2nd</suffix></name><name><surname>Stock</surname><given-names>RJ</given-names></name><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Berek</surname><given-names>JS</given-names></name><name><surname>Souhami</surname><given-names>L</given-names></name><name><surname>Grigsby</surname><given-names>P</given-names></name><name><surname>Gordon</surname><given-names>W</given-names><suffix>Jr</suffix></name><name><surname>Alberts</surname><given-names>DS</given-names></name></person-group><article-title>Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><issue>8</issue><fpage>1606</fpage><lpage>1613</lpage><pub-id pub-id-type="doi">10.1200/JCO.2000.18.8.1606</pub-id><pub-id pub-id-type="pmid">10764420</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabrini</surname><given-names>MG</given-names></name><name><surname>Gadducci</surname><given-names>A</given-names></name><name><surname>Perrone</surname><given-names>F</given-names></name><name><surname>Cosio</surname><given-names>S</given-names></name><name><surname>Laliscia</surname><given-names>C</given-names></name><name><surname>Pasqualetti</surname><given-names>F</given-names></name><name><surname>Grespi</surname><given-names>S</given-names></name><name><surname>Cionini</surname><given-names>L</given-names></name></person-group><article-title>Clinical outcome of tailored adjuvant postoperative chemoradiotherapy in IB FIGO stage cervical cancer</article-title><source>Anticancer Res</source><year>2009</year><volume>29</volume><issue>10</issue><fpage>4205</fpage><lpage>4210</lpage><pub-id pub-id-type="pmid">19846974</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehouli</surname><given-names>J</given-names></name><name><surname>Runnebaum</surname><given-names>IB</given-names></name><name><surname>Fotopoulou</surname><given-names>C</given-names></name><name><surname>Blohmer</surname><given-names>U</given-names></name><name><surname>Belau</surname><given-names>A</given-names></name><name><surname>Leber</surname><given-names>H</given-names></name><name><surname>Hanker</surname><given-names>LC</given-names></name><name><surname>Hartmann</surname><given-names>W</given-names></name><name><surname>Richter</surname><given-names>R</given-names></name><name><surname>Keyver-Paik</surname><given-names>MD</given-names></name><etal></etal></person-group><article-title>A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study</article-title><source>Ann Oncol</source><year>2012</year><volume>23</volume><issue>9</issue><fpage>2259</fpage><lpage>2264</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdr628</pub-id><pub-id pub-id-type="pmid">22357252</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TS</given-names></name><name><surname>Kang</surname><given-names>SB</given-names></name><name><surname>Kim</surname><given-names>YT</given-names></name><name><surname>Park</surname><given-names>BJ</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>KT</given-names></name></person-group><article-title>Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2013</year><volume>86</volume><issue>2</issue><fpage>304</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.01.035</pub-id><pub-id pub-id-type="pmid">23642625</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazawa</surname><given-names>M</given-names></name><name><surname>Mabuchi</surname><given-names>S</given-names></name><name><surname>Isohashi</surname><given-names>F</given-names></name><name><surname>Suzuki</surname><given-names>O</given-names></name><name><surname>Yoshioka</surname><given-names>Y</given-names></name><name><surname>Sasano</surname><given-names>T</given-names></name><name><surname>Ohta</surname><given-names>Y</given-names></name><name><surname>Kamiura</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name></person-group><article-title>Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience</article-title><source>Int J Gynecol Cancer</source><year>2013</year><volume>23</volume><issue>3</issue><fpage>567</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1097/IGC.0b013e31828703fd</pub-id><pub-id pub-id-type="pmid">23385284</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takekuma</surname><given-names>M</given-names></name><name><surname>Kasamatsu</surname><given-names>Y</given-names></name><name><surname>Kado</surname><given-names>N</given-names></name><name><surname>Kuji</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Hirashima</surname><given-names>Y</given-names></name></person-group><article-title>Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer</article-title><source>J Obstet Gynaecol Res</source><year>2015</year><volume>41</volume><issue>10</issue><fpage>1638</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1111/jog.12754</pub-id><pub-id pub-id-type="pmid">26177790</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YY</given-names></name><name><surname>Park</surname><given-names>W</given-names></name><name><surname>Huh</surname><given-names>SJ</given-names></name><name><surname>Yoon</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Choi</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>TJ</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>BG</given-names></name><name><surname>Bae</surname><given-names>DS</given-names></name></person-group><article-title>Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis</article-title><source>Anticancer Res</source><year>2013</year><volume>33</volume><issue>10</issue><fpage>4675</fpage><lpage>4681</lpage><pub-id pub-id-type="pmid">24123048</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trifiletti</surname><given-names>DM</given-names></name><name><surname>Swisher-McClure</surname><given-names>S</given-names></name><name><surname>Showalter</surname><given-names>TN</given-names></name><name><surname>Hegarty</surname><given-names>SE</given-names></name><name><surname>Grover</surname><given-names>S</given-names></name></person-group><article-title>Postoperative Chemoradiation Therapy in High-Risk Cervical Cancer: Re-evaluating the Findings of Gynecologic Oncology Group Study 109 in a Large, Population-Based Cohort</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2015</year><volume>93</volume><issue>5</issue><fpage>1032</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.09.001</pub-id><pub-id pub-id-type="pmid">26581141</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colleoni</surname><given-names>M</given-names></name><name><surname>Bonetti</surname><given-names>M</given-names></name><name><surname>Coates</surname><given-names>AS</given-names></name><name><surname>Castiglione-Gertsch</surname><given-names>M</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Price</surname><given-names>K</given-names></name><name><surname>Rudenstam</surname><given-names>CM</given-names></name><name><surname>Lindtner</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><name><surname>Thurlimann</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><issue>3</issue><fpage>584</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1200/JCO.2000.18.3.584</pub-id><pub-id pub-id-type="pmid">10653873</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arkenau</surname><given-names>HT</given-names></name><name><surname>Bermann</surname><given-names>A</given-names></name><name><surname>Rettig</surname><given-names>K</given-names></name><name><surname>Strohmeyer</surname><given-names>G</given-names></name><name><surname>Porschen</surname><given-names>R</given-names></name></person-group><article-title>5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><issue>3</issue><fpage>395</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdg100</pub-id><pub-id pub-id-type="pmid">12598344</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofstetter</surname><given-names>G</given-names></name><name><surname>Concin</surname><given-names>N</given-names></name><name><surname>Braicu</surname><given-names>I</given-names></name><name><surname>Chekerov</surname><given-names>R</given-names></name><name><surname>Sehouli</surname><given-names>J</given-names></name><name><surname>Cadron</surname><given-names>I</given-names></name><name><surname>Van Gorp</surname><given-names>T</given-names></name><name><surname>Trillsch</surname><given-names>F</given-names></name><name><surname>Mahner</surname><given-names>S</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study</article-title><source>Gynecol Oncol</source><year>2013</year><volume>131</volume><issue>1</issue><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2013.07.086</pub-id><pub-id pub-id-type="pmid">23877013</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>HS</given-names></name><name><surname>Chun</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>KH</given-names></name><name><surname>Chang</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>JP</given-names></name></person-group><article-title>Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients</article-title><source>Gynecol Oncol</source><year>2005</year><volume>96</volume><issue>2</issue><fpage>490</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2004.10.038</pub-id><pub-id pub-id-type="pmid">15661240</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolb</surname><given-names>BA</given-names></name><name><surname>Buller</surname><given-names>RE</given-names></name><name><surname>Connor</surname><given-names>JP</given-names></name><name><surname>DiSaia</surname><given-names>PJ</given-names></name><name><surname>Berman</surname><given-names>ML</given-names></name></person-group><article-title>Effects of early postoperative chemotherapy on wound healing</article-title><source>Obstet Gynecol</source><year>1992</year><volume>79</volume><issue>6</issue><fpage>988</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">1579328</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunduz</surname><given-names>N</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Saffer</surname><given-names>EA</given-names></name></person-group><article-title>Effect of surgical removal on the growth and kinetics of residual tumor</article-title><source>Cancer Res</source><year>1979</year><volume>39</volume><issue>10</issue><fpage>3861</fpage><lpage>3865</lpage><pub-id pub-id-type="pmid">476622</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Gunduz</surname><given-names>N</given-names></name><name><surname>Saffer</surname><given-names>EA</given-names></name></person-group><article-title>Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases</article-title><source>Cancer Res</source><year>1983</year><volume>43</volume><issue>4</issue><fpage>1488</fpage><lpage>1492</lpage><pub-id pub-id-type="pmid">6831397</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000C43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |